Use of prolonged bivalirudin infusions following percutaneous coronary intervention

Cardiovascular Drugs and Therapy

Volumn 25, Issue 3, 2011, Pages 267-276

  Moser, Lynette R ^a,b   Nemerovski, Carrie W ^a,c   Good, Kelley L ^d  

^a WAYNE STATE UNIVERSITY   (United States)

^b HARPER UNIVERSITY HOSPITAL   (United States)

^c HENRY FORD HOSPITAL   (United States)

^d BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

Antithrombotic; Bivalirudin; Clopidogrel; Coronary artery disease; Percutaneous coronary intervention; Prolonged infusion

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ARGATROBAN; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; THIENOPYRIDINE DERIVATIVE;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; BLEEDING; CHRONIC DRUG ADMINISTRATION; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; HEART INFARCTION; HEART MUSCLE INJURY; HUMAN; LOADING DRUG DOSE; MONOTHERAPY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, BALLOON, CORONARY; ANTITHROMBINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HIRUDINS; HUMANS; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; STENTS; THROMBOSIS; TIME FACTORS;

EID: 79958695205     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-011-6293-9     Document Type: Review

References (41)

1. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation. 2004;110:e82-e293.
2. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With UnstableAngina/Non-ST- Elevation Myocardial Infarction). Circulation. 2007;116:e148-304.
3. Kushner FG, Hand M, Smith Jr SC, et al. 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;120:2271-306.
4. Harrington RA, Becker RC, Cannon CP, et al. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians evidence-based clinical practice guidelines, 8th ed. Chest. 2008;133:670S-707S.
5. Goodman SG, Menon V, Cannon CP, et al. Acute ST-segment elevation myocardial infarction: American College of Chest Physicians evidence-based clinical practice guidelines, 8th ed. Chest. 2008;133:708S-75S.
6. Smith SC, Feldman TE, Hirscfeld JW, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2005;113:156-75.
7. Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abiximab during percutaneous coronary revascularization: results of the comparison of abciximab complication with hirulog for ischemic events trial (CACHET). Am Heart J. 2002;143:847-53. (Pubitemid 34595343)
8. Lincoff AM, Bittl JA, Kleiman NS, et al. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the randomized evaluation of PCI linking angiomax to reduced clinical events [REPLACE]-1 trial). Am J Cardiol. 2004;93:1092-6. (Pubitemid 38521035)
9. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. JAMA. 2003;289:853-63. (Pubitemid 37430344)
10. Kastrati A, Neumann F, Mehilli J, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med. 2008;359:688-96.
11. Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the bivalirudin angioplasty study. Am Heart J. 2001;142:952-9. (Pubitemid 33131801)
12. Stone GW, McLaurin BT, Cos DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203-16. (Pubitemid 44791162)
13. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218-30. (Pubitemid 351724451)
14. Kereiakes DJ. Improving adjunctive pharmacotherapy for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: beyond the HORIZONS-AMI Trial. Rev Cardiovasc Med. 2009;10:72-82.
15. Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thromb Haemost. 2008;99:830-9.
16. Bivalirudin [package insert]. Parsippany, NJ: The Medicines Company; 2005.
17. De Lucca G, Cassetti E, Verdoia M, Marino P. Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty. Thromb Haemost. 2009;102:428-36.
18. Bates SM, Weitz JI. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am J Cardiol. 1998;82:12P-8P.
19. Wiggins BS, Spinler S, Wittkowsky AK, Stringer KA. Bivalirudin: a direct thrombin inhibitor for percutaneous transluminal coronary angioplasty. Pharmacotherapy. 2002;22:1007-18. (Pubitemid 34831296)
20. Anand SX, Kim MC, Kamran M, et al. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin. Am J Cardiol. 2007;100:417-24. (Pubitemid 47094690)
21. Argatroban [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2009.
22. Lepirudin [package insert]. Toronto, Ontario, Canada; Bayer Corp; 2007.
23. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med. 1995;333:764-9.
24. Iijima R, Ndrepepa G, Mehilli J, et al. Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention. Eur Heart J. 2009;30:290-6.
25. Fuchs J, Cannon CP, the TIMI 7 Investigators. Hirulog in the treatment of unstable angina: results of the thrombin inhibition in myocardial ischemia (TIMI 7) trial. Circulation. 1995;92:727-33.
26. Antman EM, McCabe CH, Braunwald E, et al. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-STelevation myocardial infarction: Observations from the TIMI 8 trial. Am Heart J. 2002;143:229-34.
27. Stone GW, Bertrand M, Colombo A, et al. Acute catheterization and urgent intervention triage strategy (ACUITY) trial: study design and rationale. Am Heart J. 2004;148:764-75.
28. Mehran R, Brodie B, Cox DA, et al. The harmonizing outcomes with revascularization and stents in acute myocardial infarction (HORIZONS-AMI) trial: study design and rationale. Am Heart J. 2008;156:44-56. (Pubitemid 351862292)
29. Mehran R, Lansky AJ, Witzenbichler B, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomized controlled trial. Lancet. 2009;374-59.
30. Cortese B, Micheli A, Picchi A, et al. Safety and efficacy of a prolonged bivalirudin infusion after urgent and complex percutaneous coronary interventions: a descriptive study. Coron Artery Dis. 2009;20:348-53.
31. Cortese B, Picchi A, Micheli A, et al. Comparison of prolonged bivalirudin infusion versus intraprocedural in preventing myocardial damage after percutaneous coronary intervention in patients with angina pectoris. Am J Cardiol. 2009;104:1063-8.
32. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence based clinical practice guidelines 8th Edition. Chest. 2008;133: 340S-80S.
33. Kiser TH, Burch JC, Klem PM, et al. Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia. Pharmcotherapy. 2008;28:1115-24.
34. Lincoff AM, Steinhubl SR, Manoukian SV, et al. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY trial. J Am Coll Cardiol Intv. 2008;1:639-48.
35. Saw J, Lincoff M, DeSmet W, et al. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoptrotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE 2 substudy. J Am Coll Cardiol. 2004;44:1194-9. (Pubitemid 39208873)
36. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357:2482-94.
37. Dangas G, Mehran R, Guagliumi G, et al. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty. J Am Coll Cardiol. 2009;54:1438-46.
38. DeLuca G, Cassetti E, Verdoia M, Marino P. Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty: A meta-analysis of randomized trials. Thromb Haemost. 2009;102:428-36.
39. Norgard NB, Abu-Fadel M. Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Vasc Health Risk Manage. 2009;5:873-82.
40. Montalescot G, Sideris G, Meuleman C, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION trial. J Am Coll Cardiol. 2006;48:931-8.
41. Wallentin L. P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J. 2009;30:1964-77.